Neophore appoints Dr John Haurum Neophore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John Haurum as Non-Executive Director with immediate effect. more ➔
Mats Blom joins Modus as CFO Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs and a focus on sickle cell disease (SCD), announces the appointment of Mats Blom as Chief … more ➔
Miranda Wolpert joins Wellcome Miranda Wolpert, MBE, an expert on child and adolescent mental health has joined the London-based Wellcome Trust as head of their mental health priority area. more ➔
Neurimmune appoints John DellapaNeurimmune today announced the appointment of John Dellapa as General Counsel. John joins Neurimmune from the Boston office of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, an AmLaw 100 law fi … more ➔
Mundipharma appoints Patrice Grand Mundipharma today announced the appointment of Patrice Grand to the position of European Director of Corporate Communications. more ➔
Sanofi appoints Ameet Nathwani Sanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer. more ➔
Kiadis Pharma appoints Dr. Robert Friesen... Kiadis Pharma N.V., a clinical-stage biopharmaceutical company, on Monday announced the appointment of Robert Friesen, PhD as Chief Scientific Officer (CSO) effective February 1, 2019. more ➔
Rentschler Biopharma SE appoints Dr. Chris... Rentschler Biopharma SE announced today the appointment of Dr. Christian Hunzinger as the new Senior Vice President Project Management, effective from January 15, 2019. more ➔
Valbiotis appoints Josep Infesta Valbiotis, a French research and development company committed to preventing and combating metabolic diseases, today on 24 January the appointment of Josep Infesta as Head of Global Business Development. more ➔
Asceneuron appoints Peter Van Vlasselaer Asceneuron, a company in the development of orally bioavailable modulators of tau pathology for the treatment of neurodegenerative diseases, today announces the appointment of Peter Van Vlasselaer as … more ➔
